Anne-Sophie Adam

Mrs. Anne-Sophie Adam

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BGBEATRICE GULBIS
BEATRICE GULBIS
PLPhu-Quoc Lê
Phu-Quoc Lê
OKOlivier Ketelslegers
Olivier Ketelslegers
MDMarie-Françoise Dresse
Marie-Françoise Dresse
AAAnne-Sophie Adam
Anne-Sophie Adam
AFAlina Ferster
Alina Ferster
Our previous results reported that compared to sickle cell patients who were not screened at birth, those who benefited from it had a lower incidence of a first bacteremia and a reduced number and days of hospitalizations. In this context, this article reviews the Belgian experience on neonatal screening for sickle cell disease (SCD). It gives an update on the two regional neonatal screening programs for SCD in Belgium and their impact on initiatives to improve clinical care for sickle cell patients. Neonatal screening in Brussels and Liège Regions began in 1994 and 2002, respectively. Compiled results for the 2009 to 2017 period demonstrated a birth prevalence of sickle cell disorder above 1:2000. In parallel, to improve clinical care, (1) a committee of health care providers dedicated to non-malignant hematological diseases has been created within the Belgian Haematology Society; (2) a clinical registry was implemented in 2008 and has been updated in 2018; (3) a plan of action has been proposed to the Belgian national health authority. To date, neonatal screening is not integrated into the respective Belgian regional neonatal screening programs, the ongoing initiatives in Brussels and Liège Regions are not any further funded and better management of the disease through the implementation of specific actions is not yet perceived as a public health priority in Belgium.

22 April 2022 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
AAAnne-Sophie Adam
Anne-Sophie Adam
FCFrédéric Cotton
Frédéric Cotton
BCBrigitte Cantinieaux
Brigitte Cantinieaux
SBSara Benyaich
Sara Benyaich
BGBéatrice Gulbis
Béatrice Gulbis

26 October 2026 in American Journal of Hematology
Verified
Journal Article
Closed access
ZHZachary B. Haiman
Zachary B. Haiman
Alkmini AnastasiadiAlkmini Anastasiadi
Alkmini Anastasiadi
PDPolyxeni Delaporta
Polyxeni Delaporta
DSDaniel Stephenson
Daniel Stephenson
MDMonika Dzieciatkowska
Monika Dzieciatkowska
Angelo D'AlessandroAngelo D'Alessandro
Angelo D'Alessandro

7 January 2026 in JIMD Reports
Verified
Journal Article
Open access
AAAnne-Sophie Adam
Anne-Sophie Adam
LMLionel Marcélis
Lionel Marcélis
DFDavid Fage
David Fage
EMElise Mathieu
Elise Mathieu
AEAurélie Empain
Aurélie Empain
CLCorinne de Laet
Corinne de Laet
Hereditary tyrosinemia type I (HT‐1) is a rare metabolic disorder treated by NTBC, requiring careful therapeutic and nutritional monitoring. While follow‐up traditionally relies on urinary succinylacetone, plasma NTBC and plasma amino acids, dried blood spot (DBS) methods have introduced alternative monitoring options. However, the optimal biochemical monitoring remains debated. This study evaluated the clinical utility of NTBC measurements compared with established biomarkers in HT‐1. In this retrospective single‐centre study, we analysed biological data from 12 HT‐1 patients treated with NTBC over 6 years. We analysed correlations between NTBC, succinylacetone, δ‐aminolevulinic acid (δ‐ALA) and alpha‐fetoprotein concentrations, and compared tyrosine and phenylalanine levels in DBS and plasma. Succinylacetone suppression in both urine and blood was achieved across a broad range of NTBC concentrations, suggesting that blood succinylacetone is a more reliable marker of metabolic control than NTBC levels. Elevated urinary δ‐ALA levels were observed in some samples despite unquantifiable succinylacetone, indicating that succinylacetone may not fully reflect neurological risk. NTBC concentrations showed limited correlation with alpha‐fetoprotein, reinforcing the continued need for imaging in hepatocellular carcinoma surveillance. DBS measurement of tyrosine and phenylalanine displayed variable biases relative to plasma, particularly for tyrosine, highlighting the challenges of using DBS for nutritional monitoring. While NTBC remains central in the treatment of HT‐1 patients, its blood concentrations offer limited added value for long‐term monitoring. Focusing on succinylacetone measurement, along with δ‐ALA and alpha‐fetoprotein to evaluate neurological and hepatic risks, is recommended. Plasma remains the preferred matrix for amino acids monitoring. Larger multi‐centre studies are needed to confirm these findings.

10 November 2025 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
AAAnne-Sophie Adam
Anne-Sophie Adam
FCFrédéric Cotton
Frédéric Cotton
DPDanai Poutakidou
Danai Poutakidou
BGBéatrice Gulbis
Béatrice Gulbis

26 January 2022 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
AAAnne-Sophie Adam
Anne-Sophie Adam
SBSara Benyaich
Sara Benyaich
MCMartin Colard
Martin Colard
FBFleur Samantha Benghiat
Fleur Samantha Benghiat
FCFrédéric Cotton
Frédéric Cotton
BGBéatrice Gulbis
Béatrice Gulbis
Article Rare unstable and low oxygen affinity haemoglobin variant, Hb Hazebrouck, detected on Sysmex XN-9000 was published on January 26, 2022 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).